BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 21042711)

  • 1. Efficacy of oncolytic reovirus against human gastric cancer with peritoneal metastasis in experimental animal model.
    Kawaguchi K; Etoh T; Suzuki K; Mitui MT; Nishizono A; Shiraishi N; Kitano S
    Int J Oncol; 2010 Dec; 37(6):1433-8. PubMed ID: 21042711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reovirus inhibits the peritoneal dissemination of pancreatic cancer cells in an immunocompetent animal model.
    Hirano S; Etoh T; Okunaga R; Shibata K; Ohta M; Nishizono A; Kitano S
    Oncol Rep; 2009 Jun; 21(6):1381-4. PubMed ID: 19424613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional administration of oncolytic Echovirus 1 as a novel therapy for the peritoneal dissemination of gastric cancer.
    Haley ES; Au GG; Carlton BR; Barry RD; Shafren DR
    J Mol Med (Berl); 2009 Apr; 87(4):385-99. PubMed ID: 19139835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomerase-specific oncolytic adenovirus expressing TRAIL suppresses peritoneal dissemination of gastric cancer.
    Zhou W; Dai S; Zhu H; Song Z; Cai Y; Lee JB; Li Z; Hu X; Fang B; He C; Huang X
    Gene Ther; 2017 Apr; 24(4):199-207. PubMed ID: 28075429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
    Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer.
    Tsuji T; Nakamori M; Iwahashi M; Nakamura M; Ojima T; Iida T; Katsuda M; Hayata K; Ino Y; Todo T; Yamaue H
    Int J Cancer; 2013 Jan; 132(2):485-94. PubMed ID: 22729516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic.
    Thirukkumaran CM; Nodwell MJ; Hirasawa K; Shi ZQ; Diaz R; Luider J; Johnston RN; Forsyth PA; Magliocco AM; Lee P; Nishikawa S; Donnelly B; Coffey M; Trpkov K; Fonseca K; Spurrell J; Morris DG
    Cancer Res; 2010 Mar; 70(6):2435-44. PubMed ID: 20215509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenoviral oncolytic suicide gene therapy for a peritoneal dissemination model of gastric cancer in mice.
    Imamura Y; Ishikawa S; Sato N; Karashima R; Hirashima K; Hiyoshi Y; Nagai Y; Koga Y; Hayashi N; Watanabe M; Yamada G; Baba H
    Ann Surg Oncol; 2010 Feb; 17(2):643-52. PubMed ID: 20012217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells.
    Hamano S; Mori Y; Aoyama M; Kataoka H; Tanaka M; Ebi M; Kubota E; Mizoshita T; Tanida S; Johnston RN; Asai K; Joh T
    Cancer Lett; 2015 Jan; 356(2 Pt B):846-54. PubMed ID: 25444894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases.
    Yang A; Zhang Z; Chaurasiya S; Park AK; Jung A; Lu J; Kim SI; Priceman S; Fong Y; Woo Y
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37019471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of Reoviral Cytolysis (I): Combination Therapeutics.
    Mori Y; Nishikawa SG; Fratiloiu AR; Tsutsui M; Kataoka H; Joh T; Johnston RN
    Viruses; 2023 Jun; 15(7):. PubMed ID: 37515160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma.
    Lawson KA; Mostafa AA; Shi ZQ; Spurrell J; Chen W; Kawakami J; Gratton K; Thakur S; Morris DG
    Clin Cancer Res; 2016 Dec; 22(23):5839-5850. PubMed ID: 27220962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms in the Most Oncolytic Reovirus Strain Confer Enhanced Cell Attachment, Transcription, and Single-Step Replication Kinetics.
    Mohamed A; Smiley JR; Shmulevitz M
    J Virol; 2020 Jan; 94(4):. PubMed ID: 31776267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraperitoneal administration of a small interfering RNA targeting nuclear factor-kappa B with paclitaxel successfully prolongs the survival of xenograft model mice with peritoneal metastasis of gastric cancer.
    Inoue M; Matsumoto S; Saito H; Tsujitani S; Ikeguchi M
    Int J Cancer; 2008 Dec; 123(11):2696-701. PubMed ID: 18798274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.
    Nanni P; Gatta V; Menotti L; De Giovanni C; Ianzano M; Palladini A; Grosso V; Dall'ora M; Croci S; Nicoletti G; Landuzzi L; Iezzi M; Campadelli-Fiume G; Lollini PL
    PLoS Pathog; 2013 Jan; 9(1):e1003155. PubMed ID: 23382683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Construction of a new oncolytic virus oHSV2hGM-CSF and its anti-tumor effects].
    Shi GL; Zhuang XF; Han XP; Li J; Zhang Y; Zhang SR; Liu BL
    Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):89-95. PubMed ID: 22780924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro.
    Alain T; Kim M; Johnston RN; Urbanski S; Kossakowska AE; Forsyth PA; Lee PW
    Br J Cancer; 2006 Oct; 95(8):1020-7. PubMed ID: 17047650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors.
    Kapadia R; Coffey MC
    Methods; 2010 Dec; 52(4):301-6. PubMed ID: 20801221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of oncolytic reovirus against liver metastasis from pancreatic cancer in immunocompetent models.
    Himeno Y; Etoh T; Matsumoto T; Ohta M; Nishizono A; Kitano S
    Int J Oncol; 2005 Oct; 27(4):901-6. PubMed ID: 16142304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of Genetically RGD σ1-Modified Oncolytic Reovirus That Enhances JAM-A-Independent Infection of Tumor Cells.
    Kawagishi T; Kanai Y; Nouda R; Fukui I; Nurdin JA; Matsuura Y; Kobayashi T
    J Virol; 2020 Nov; 94(23):. PubMed ID: 32907973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.